Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Promising Preclinical Combinations of AFM13 and Natural Killer Cells Presented at SITC
Heidelberg, Germany, November 9, 2020 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
News
LLS Statement on Oral Arguments in California v. Texas
This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act.
Sanofi offers to acquire Kiadis for €308 million
Paris, France and Amsterdam, The Netherlands, 2 November 2020 – Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a…
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
GAITHERSBURG, MD - October 27, 2020 - NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunother…
Research
HCL2025 guidelines
The HCLF and LLS joining forces to expanding research in Hairy Cell Leukemia to better characterize its biology, develop new therapies, and optimize o…
News
Study in Nature Medicine Shows Superior Outcomes for Patients in LLS's Paradigm-Shifting Beat AML Clinical Trial
Bringing Precision Medicine to AML patients: LLS’S Beat AML® Master Clinical Trial
OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the developm…
Patient Education Webcasts
Understanding Myeloma
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
